Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Julphar
Farmers Insurance
Federal Trade Commission
McKesson
Fish and Richardson
Moodys
AstraZeneca
US Department of Justice

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,451,340

« Back to Dashboard

Which drugs does patent 6,451,340 protect, and when does it expire?

Patent 6,451,340 protects HEPSERA and is included in one NDA.

This patent has fifty-six patent family members in twenty-five countries.
Summary for Patent: 6,451,340
Title: Nucleotide analog compositions
Abstract:The invention provides crystalline forms of adefovir dipivoxil and methods to prepare the crystals. The compositions and methods of the present invention have desirable properties for large scale synthesis of crystalline adefovir dipivoxil or for its formulation into therapeutic dosages. Invention compositions include an anhydrous crystal form of adefovir dipivoxil.
Inventor(s): Arimilli; Murty N. (Fremont, CA), Kelly; Daphne E. (San Francisco, CA), Lee; Thomas T. K. (Redwood City, CA), Manes; Lawrence V. (Moss Beach, CA), Munger, Jr.; John D. (Alviso, CA), Prisbe; Ernest J. (Los Altos, CA), Schultze; Lisa M. (San Carlos, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:09/950,031
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,451,340
Patent Claim Types:
see list of patent claims
Composition; Use; Formulation; Process; Dosage form;

Drugs Protected by US Patent 6,451,340

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead HEPSERA adefovir dipivoxil TABLET;ORAL 021449-001 Sep 20, 2002 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,451,340

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 016548 ➤ Try a Free Trial
Austria 228357 ➤ Try a Free Trial
Austria 277936 ➤ Try a Free Trial
Austria 277937 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Cipla
Cantor Fitzgerald
Covington
Colorcon
Citi
Accenture
Federal Trade Commission
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.